Cytek Biosciences (CTKB) Current Assets (2020 - 2026)

Cytek Biosciences has reported Current Assets for 7 years, with the latest figure at $379.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets changed 0.32% year-over-year to $379.3 million; the trailing twelve-month figure through Mar 2026 stood at $379.3 million (changed 0.32% YoY), and the FY2025 full-year result was $392.0 million, down 1.12% from the prior year.
• Current Assets for Q1 2026 stood at $379.3 million, down from $392.0 million in the prior quarter.
• The five-year high for Current Assets was $454.0 million in Q4 2022, with the low at $379.3 million in Q1 2026.
• Historically, Current Assets has averaged $407.5 million across 5 years, with a median of $392.1 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets jumped 104.33% — and 2023, when it declined 13.65%.
• Cytek Biosciences' Current Assets stood at $454.0 million in 2022, then retreated by 13.65% to $392.1 million in 2023, then rose by 1.12% to $396.4 million in 2024, then decreased by 1.12% to $392.0 million in 2025, then dropped by 3.24% to $379.3 million in 2026.
• The last three Current Assets figures came in at $379.3 million (Q1 2026), $392.0 million (Q4 2025), and $388.5 million (Q3 2025), per Business Quant data.